MedElevator
Войти в исследования Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huaman Moises A, Raval Jay S, Paxton James H, Mosnaim Giselle S, Patel Bela, Anjan Shweta, Meisenberg Barry R, Levine Adam C, Marshall Christi E, Yarava Anusha, Shenoy Aarthi G, Heath Sonya L, Currier Judith S, Fukuta Yuriko, Blair Janis E, Spivak Emily S, Petrini Joann R, Broderick Patrick B, Rausch William, Cordisco MarieElena, Hammel Jean, Greenblatt Benjamin, Cluzet Valerie C, Cruser Daniel, Oei Kevin, Abinante Matthew, Hammitt Laura L, Sutcliffe Catherine G, Forthal Donald N, Zand Martin S, Cachay Edward R, Kassaye Seble G, Ram Malathi, Wang Ying, Das Piyali, Lane Karen, McBee Nichol A, Gawad Amy L, Karlen Nicky, Ford Daniel E, Laeyendecker Oliver, Pekosz Andrew, Klein Sabra L, Ehrhardt Stephan, Lau Bryan, Baksh Sheriza N, Shade David M, Casadevall Arturo, Hanley Daniel F, Ou Jiangda, Gniadek Thomas J, Ziman Alyssa, Shoham Shmuel, Gebo Kelly A, Bloch Evan M, Tobian Aaron A R, Sullivan David J, Gerber Jonathan M
Аннотация
STUDY DESIGN AND METHODS: We analyzed data pertaining to transfusion-related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.
RESULTS: The combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic-type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID-19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43-1.31). Risk of urticaria and/or pruritus increased with a pre-existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16-4.67). We did not observe any CCP-attributed antibody disease enhancement in participants with COVID-19 or increased risk of infection. There were no life-threatening severe transfusion reactions and no patients required hospitalization related to transfusion-associated complications.
DISCUSSION: Outpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID-19.